The drug, known scientifically as ticagrelor, was approved by the FDA in 2011 despite widespread pushback from scientists over concerns about its trial results. Since then, a number of studies ...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.

Nevertheless, the new sub-analysis could provide a significant boost for Brilinta, as the data suggest treating patients for longer with the drug can prevent more from suffering a second ...

HealthDay News — For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES ... the effects of de-escalating DAPT to ticagrelor monotherapy vs standard DAPT using ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

Ongoing studies of prasugrel should help determine whether this drug has a role in the initial medical management of ACS. Given the benefits of ticagrelor over clopidogrel seen in PLATO ...

Ticagrelor monotherapy as used in the TWILIGHT ... to be safer than ticlopidine and stent thrombosis with the early drug-eluting stents seemed to be lessened with more prolonged DAPT.

An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...